logo
Tennis Hall of Famer Monica Seles Opens Up About Myasthenia Gravis Diagnosis: 'It's a Difficult One'

Tennis Hall of Famer Monica Seles Opens Up About Myasthenia Gravis Diagnosis: 'It's a Difficult One'

Yahoo14 hours ago
The nine-time major tennis champion is raising awareness about the neuromuscular disease ahead of this month's U.S. OpenNEED TO KNOW
Tennis Hall of Famer Monica Seles is opening up about her Myasthenia Gravis diagnosis
Seles, a nine-time major tennis champion, said adjusting to life with the disease has been "difficult"
Seles is partnering with a Dutch immunology company to raise awareness about the neuromuscular diseaseMonica Seles is opening up about a neuromuscular disease diagnosis that has impacted her daily life 'quite a lot' in recent years.
The International Tennis Hall of Famer, 51, revealed to the Associated Press that she was diagnosed three years ago with myasthenia gravis, a neuromuscular autoimmune disease that causes a person's muscles to feel weak and quickly grow tired.
In addition to muscle weakness, according to the Mayo Clinic, myasthenia gravis can cause a person to have double vision and drooping eyelids. It can also cause problems speaking, breathing, swallowing and chewing. There is no cure for the disease.
The retired Serbian-American women's tennis star told the AP she began noticing symptoms of the disease while playing tennis with her family and began seeing multiple balls coming toward her.
'I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore,' Seles said.
'And, for me, this is when this journey started. And it took me quite some time to really absorb it, speak openly about it, because it's a difficult one," she continued. "It affects my day-to-day life quite a lot."
Seles told the outlet that routine daily tasks like doing her hair 'became very difficult' to manage. The nine-time grand slam tennis champion told the AP she had never heard of the disease before she was diagnosed, inspiring her to speak up about it now ahead of the U.S. Open, which begins next week.
'When I got diagnosed, I was like, 'What?!'' Seles recalled. 'So this is where — I can't emphasize enough — I wish I had somebody like me speak up about it.'
Seles is partnering with a Dutch immunology company as a primary spokesperson for its 'Go for Greater' campaign to help those living with myasthenia gravis find resources to help them manage their life with the disease.
https://people-app.onelink.me/HNIa/kz7l4cuf
The tennis great told the AP that her diagnosis has led her to go through yet another 'hard reset' in her life, equating the experience to some of her biggest career hurdles.
Seles won eight grand slam titles as a teenager and was widely regarded to be on her way to becoming one of the most accomplished tennis stars in history when she was stabbed by a fan on the court during a match in 1993, after which she stepped away from tennis for two years.
She returned to tennis in 1995 and won one more major championship, her ninth overall, before retiring for good in 2003.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories.
'I call my first hard reset when I came to the U.S. as a young 13-year-old [from Yugoslavia]. Didn't speak the language [and] left my family,' Seles told the AP.
She added, 'It's a very tough time. Then, obviously, becoming a great player, it's a reset, too, because the fame, money, the attention, changes [everything], and it's hard as a 16-year-old to deal with all that. Then obviously my stabbing — I had to do a huge reset.''And then, really, being diagnosed with myasthenia gravis: another reset," she said. "But one thing, as I tell kids that I mentor: 'You've got to always adjust. That ball is bouncing, and you've just got to adjust.' And that's what I'm doing now.'
Read the original article on People
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Blood Oxygen Sensing Is Finally Returning to the Apple Watch
Blood Oxygen Sensing Is Finally Returning to the Apple Watch

WIRED

timean hour ago

  • WIRED

Blood Oxygen Sensing Is Finally Returning to the Apple Watch

Aug 14, 2025 11:49 AM The feature was removed on select smartwatches due to a patent infringement lawsuit, but Apple has 'redesigned' it. Photo-Illustration:All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. If you have an Apple Watch Series 9, 10, or Ultra Watch 2 that you bought in the US in the past year, you'll finally get the Blood Oxygen sensing feature back via a software update later today, according to Apple. To make sure you get the feature, update your paired iPhone to iOS 18.6.1 and the Apple Watch to watchOS 11.6.1. Sensor data will be calculated in the app, and you will be able to see your blood oxygen in the Respiratory section of the Health app. If you bought your watch before 2024 or outside of the US, you won't see any changes. A recent US Customs ruling resolved a years-long dispute with health tech company Masimo. In 2021, Masimo sued Apple, claiming the Apple Watch maker infringed on one of its patents for optical blood monitoring. A judge ruled that Apple infringed on the patent, and the International Trade Commission upheld that ruling. Apple was forced to suspend sales of the two offending products from 2023 to 2024. When the company launched the Apple Watch Series 10 on its landmark 10th anniversary, it was forced to do so without the blood oxygen sensing feature. This feature was originally launched on the Watch Series 6 in 2020 and has since become a core feature on almost every fitness tracker. Apple says it 'redesigned' the feature, but didn't share more details. This update fixes the single biggest problem on Apple's latest watches. Many other fitness trackers, like Garmin, have included a blood oxygen sensing feature for years. High-end trackers use the sensor data to help athletes train at altitude for optimum performance, but the feature became more important during the Covid-19 pandemic. You might not necessarily notice your blood oxygen level dipping, but your watch can. Sales of pulse oximeters skyrocketed. I myself realized that my cough was pneumonia when my blood oxygen level started dipping to around 84 percent. (An abnormal blood oxygen rating is not enough information to diagnose illness, and you should see a doctor if you get a worrisome reading from your device.) This is a positive development for Apple ahead of its annual September event, where it's expected to debut new iPhones and the Apple Watch Series 11, which will inevitably introduce more extensive health features.

QuidelOrtho launches certified analyser programme for rural health facilities
QuidelOrtho launches certified analyser programme for rural health facilities

Yahoo

timean hour ago

  • Yahoo

QuidelOrtho launches certified analyser programme for rural health facilities

QuidelOrtho has launched a Certified Analyzer Program, aimed at increasing the availability of diagnostic testing in rural and community hospitals throughout the US. The initiative targets clinics, physician office laboratories, and smaller hospitals with a capacity of less than 100 beds. The program includes certified VITROS analysers, which are said to provide 'proven reliability and quality results'. Each analyser is subjected to a detailed certification process at QuidelOrtho's facility in Rochester, which involves more than 140 system checks, functional adjustments, hardware maintenance or replacement, and thorough performance evaluations. This certification ensures that the analysers conform to QuidelOrtho's quality and performance benchmarks, and each unit is supported by a 12-month warranty for service and support. The programme features the certified VITROS XT 7600 and 5600 Integrated Systems, along with the VITROS 3600 Immunodiagnostic System. These systems enable community laboratories to perform general chemistry tests, immunoassays, and drug screenings. QuidelOrtho North America senior vice-president Audra Jones said: 'Our mission is rooted in equipping our customers so they can deliver diagnostic excellence to patients. 'By repurposing and rigorously certifying high-performing analysers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities. 'We're proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction. 'This programme isn't just about affordability; it's designed to improve accessibility and access of diagnostic solutions for healthcare providers in underserved communities.' "QuidelOrtho launches certified analyser programme for rural health facilities" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Over A Third of US Adults Are Unaware of HPV
Over A Third of US Adults Are Unaware of HPV

Medscape

timean hour ago

  • Medscape

Over A Third of US Adults Are Unaware of HPV

TOPLINE: Human papillomavirus (HPV) awareness remained critically low across the US between 2017 and 2020, with over one third of adults unaware of HPV and its corresponding vaccine. This was particularly true in Midwestern and Southern states, regions in which HPV-associated cancers are rising, and vaccination rates are suboptimal. METHODOLOGY: About 48,000 HPV-associated cancers are diagnosed annually in the US, predominantly in Midwestern and Southern states. Public awareness of HPV and its vaccine is crucial for increasing vaccination rates and preventing these cancers. Using data from the 2017-2020 Health Information National Trends Survey (HINTS) 5 Cycles 1-4 and 2022 HINTS Cycle 6 in the US, researchers assessed the awareness of HPV, HPV vaccine, and its role in causing cervical and oral cancers among 22,344 respondents (mean age, 49 years; 51.1% women). Participants responded to questions such as 'Have you ever heard of HPV?' and 'Before today, have you ever heard of the cervical cancer vaccine or HPV shot?' Those who had heard of HPV were asked, 'Do you think HPV can cause oral cancer?' and 'Do you think HPV can cause cervical cancer?' A response of 'no' or 'not sure' indicated lack of awareness about HPV. TAKEAWAY: Overall, 34.3% of adults lacked awareness about HPV, whereas 37.6% were unaware of the HPV vaccine. Among those aware of HPV, 70.8% did not know HPV causes oral cancer, whereas 28.3% were unaware of its link to cervical cancer. More than 60% of individuals in 45 states and Washington, DC, were unaware that HPV causes oral cancer, whereas unawareness of its link to cervical cancer varied widely (6.9%-57.4%). Awareness about HPV was lacking in over 40% of adults in seven states, predominantly from the Midwest and the South. Likewise, awareness about HPV vaccine was lacking in more than 40% of adults in 13 states, with nine being from the Midwest and the South. IN PRACTICE: 'In conclusion, given the importance of timely HPV vaccination and the risk of early-life exposure, there is a critical need to enhance HPV awareness among adolescents, young adults, parents or caregivers, and pediatric and adult healthcare professionals,' the authors of the study wrote. SOURCE: This study, led by Ashvita Garg, PhD, MPH, MBBS, Medical University of South Carolina in Charleston, South Carolina, was published online in JAMA Oncology. LIMITATIONS: The cross-sectional nature of the data prevented causal inferences, while the ecological nature of the analyses and limited sample sizes for certain states affected the generalizability of findings. DISCLOSURES: The research was supported by grants from the National Institute on Minority Health and Health Disparities, the National Library of Medicine, and the National Cancer Institute. One author disclosed receiving personal fees from Merck, grants and nonfinancial support from Stryker, and serving as deputy editor for JAMA Otolaryngology-Head & Neck Surgery. Another author reported receiving personal fees from Value Analytics Labs, outside the submitted work. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store